Next Article in Journal
Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development
Previous Article in Journal
Time-Resolved Studies of Ytterbium Distribution at Interfacial Surfaces of Ferritin-like Dps Protein Demonstrate Metal Uptake and Storage Pathways
Correction published on 22 March 2022, see Biomedicines 2022, 10(4), 733.

IGF1R as a Potential Pharmacological Target in Allergic Asthma

Lung Cancer and Respiratory Diseases Unit, Center for Biomedical Research of La Rioja (CIBIR), Fundación Rioja Salud, 26006 Logroño, Spain
Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), 28029 Madrid, Spain
Thoracic Oncology, Research Institute Hospital 12 de Octubre, 28041 Madrid, Spain
Department of Physiology, Faculty of Medicine, Complutense University, 28040 Madrid, Spain
Department of Respiratory Medicine, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain
Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain
Spanish Biomedical Research Networking Centre-CIBERES, 15706 Santiago de Compostela, Spain
Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain
Author to whom correspondence should be addressed.
Academic Editor: Marc Ekker
Biomedicines 2021, 9(8), 912;
Received: 10 July 2021 / Revised: 22 July 2021 / Accepted: 24 July 2021 / Published: 29 July 2021 / Corrected: 22 March 2022
(This article belongs to the Topic Animal Model in Biomedical Research)
Background: Asthma is a chronic lung disease characterized by reversible airflow obstruction, airway hyperresponsiveness (AHR), mucus overproduction and inflammation. Although Insulin-like growth factor 1 receptor (IGF1R) was found to be involved in asthma, its pharmacological inhibition has not previously been investigated in this pathology. We aimed to determine if therapeutic targeting of IGF1R ameliorates allergic airway inflammation in a murine model of asthma. Methods: C57BL/6J mice were challenged by house dust mite (HDM) extract or PBS for four weeks and therapeutically treated with the IGF1R tyrosine kinase inhibitor (TKI) NVP-ADW742 (NVP) once allergic phenotype was established. Results: Lungs of HDM-challenged mice exhibited a significant increase in phospho-IGF1R levels, incremented AHR, airway remodeling, eosinophilia and allergic inflammation, as well as altered pulmonary surfactant expression, all of being these parameters counteracted by NVP treatment. HDM-challenged lungs also displayed augmented expression of the IGF1R signaling mediator p-ERK1/2, which was greatly reduced upon treatment with NVP. Conclusions: Our results demonstrate that IGF1R could be considered a potential pharmacological target in murine HDM-induced asthma and a candidate biomarker in allergic asthma. View Full-Text
Keywords: asthma; allergy; house dust mite; IGF1R; NVP-ADW742; pharmacological blockade asthma; allergy; house dust mite; IGF1R; NVP-ADW742; pharmacological blockade
Show Figures

Figure 1

MDPI and ACS Style

Alfaro-Arnedo, E.; López, I.P.; Piñeiro-Hermida, S.; Ucero, Á.C.; González-Barcala, F.J.; Salgado, F.J.; Pichel, J.G. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines 2021, 9, 912.

AMA Style

Alfaro-Arnedo E, López IP, Piñeiro-Hermida S, Ucero ÁC, González-Barcala FJ, Salgado FJ, Pichel JG. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines. 2021; 9(8):912.

Chicago/Turabian Style

Alfaro-Arnedo, Elvira, Icíar P. López, Sergio Piñeiro-Hermida, Álvaro C. Ucero, Francisco J. González-Barcala, Francisco J. Salgado, and José G. Pichel. 2021. "IGF1R as a Potential Pharmacological Target in Allergic Asthma" Biomedicines 9, no. 8: 912.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop